Eurointervention

Papers
(The TQCC of Eurointervention is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
The conundrum of percutaneous coronary intervention without aspirin: a call for clarity181
Double-tap to treat paravalvular leak in high-risk annuli148
Transcatheter left ventriculoplasty141
In search of the origin of the acronym TAVI132
Recanalisation of coronary chronic total occlusions110
Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease; from the multicentre international ILIAS registry95
Development and validation of a scoring system for predicting clinical coronary artery perforation during percutaneous coronary intervention of chronic total occlusions: the PROGRESS-CTO perforation s92
Long-term outcomes of measured and predicted prosthesis-patient mismatch following transcatheter aortic valve replacement82
Should we routinely use ultrasound-guided transfemoral access for coronary procedures? High-quality evidence from an individual participant data meta-analysis68
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation61
Transcatheter edge-to-edge repair with the PASCAL device for failed MitraClip procedure56
Defer-based non-stenting: a promising approach for STEMI56
Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document49
The “road travelled”: reflections on the transformation of information exchange in a digital age49
Hybrid coronary revascularisation: the best or the worst of both worlds?49
   Atrial fibrillation and acute coronary syndrome 47
One-month DAPT after acute coronary syndrome: too short or not too short?44
Life expectancy of patients with a transcatheter aortic valve and the implications for long-term valve durability data collection42
Hertz contact intravascular lithotripsy for calcified coronary artery disease: the PINNACLE-I trial41
Transcatheter edge-to-edge valve repair versus minimally invasive beating-heart surgery of the tricuspid valve: an observational study41
Incidence and mechanisms of bioprosthetic dysfunction after transcatheter implantation of a mechanically-expandable heart valve39
Redo transcatheter mitral valve replacement in mitral annular calcification38
Outcomes of newly diagnosed atrial fibrillation in patients with acute coronary syndromes34
Invasive functional testing in the cath lab as a routine investigation in INOCA: pros and cons34
A novel robotic radiation shielding device for interventional cardiology procedures34
Impact of off-hours admissions in STEMI-related cardiogenic shock managed with microaxial flow pump – insights from J-PVAD34
Outcomes and performance of the ACURATE neo2 transcatheter heart valve in clinical practice: one-yearresults of the ACURATE neo2 PMCF Study33
Early outcomes of transcatheter versus surgical aortic valve implantation in patients with bicuspid aortic valve stenosis33
Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I study32
Long-term risk of unplanned percutaneous coronary intervention after transcatheter aortic valve replacement32
A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial32
Chordal replacement and annuloplasty in one transfemoral device for degenerative mitral regurgitation31
Prevalence and outcomes of stent thrombosis with in-stent calcified nodules: substudy from the REAL-ST registry30
Five-year follow-up of transcatheter tricuspid valve replacement with the EVOQUE valve28
Antithrombotic therapy for transcatheter structural heart intervention28
ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation27
Retrievable scaffold therapy before paclitaxel drug-coated balloon angioplasty in infrapopliteal arteries: one-year outcomes of the DEEPER OUS Study27
Oesophageal and gastric injuries caused by transoesophageal probe manipulation in patients undergoing transcatheter edge-to-edge repair for tricuspid regurgitation26
A nationwide analysis of reperfusion therapies for pulmonary embolism in older patients with frailty26
Coronary lithotripsy for the treatment of underexpanded stents: the international multicentre CRUNCH registry26
Cerebral embolic protection during transcatheter heart interventions25
Shifting focus in bifurcations.25
TAVI patients with bystander coronary artery disease should receive PCI: pros and cons24
Optical coherence tomography to visualise the endothelialisation of left atrial appendage occluders24
Delayed hospitalisation for heart failure after transcatheter repair or medical treatment for secondary mitral regurgitation: a landmark analysis of the MITRA-FR trial23
Carbon footprint of diagnostic coronary angiography23
Prevention of left ventricular outflow tract obstruction in transapical mitral valve replacement: the MitraCut procedure23
Is transcatheter aortic valve implantation safe in patients with left ventricular outflow tract calcification?22
Determinants of adverse outcomes following patent foramen ovale closure in elderly patients22
The ongoing conundrum of the best care for patients presenting with non-ST-segment elevation acute coronary syndrome21
Ticagrelor-based antiplatelet therapy after percutaneous coronary intervention in chronic coronary syndrome20
UNICA − a novel single-stent, double-valve, heterotopic, cross-caval approach for severe tricuspid insufficiency 19
Coronary CT as a first-line investigation in chronic coronary syndromes: pros and cons19
The patent foramen ovale does not spontaneously close in patients aged 6018
FFRangio-guided versus pressure wire-guided PCI: design and rationale of the multicentre, randomised ALL-RISE trial18
Transcatheter treatment of bicuspid aortic valve stenosis18
Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial18
New-onset atrial fibrillation detected by ambulatory ECG monitoring after transcatheter aortic valve implantation18
TRICURE: first-in-human study of the Topaz transcatheter tricuspid heart valve system18
Predictors and clinical impact of worsening left ventricular ejection fraction after mitral transcatheter edge-to-edge repair17
Near-infrared spectroscopy to predict plaque progression in plaque-free artery regions17
Diagnostic accuracy of quantitative flow ratio in patients with arrhythmias17
Targeting inflammation in atherosclerosis: overview, strategy and directions16
SAPIEN 3 Ultra: better sealing, reduced paravalvular leak and a move in the right direction?15
Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation15
Stent underexpansion in the CRUNCH registry: worth cracking?15
Three-year outcomes of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic stenosis15
Anterior mitral leaflet modification with endoscopic scissors during Tendyne implantation14
Transcatheter aortic valve alignment: substantial progress, remaining gaps13
Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI13
Letter: Caffeine and fractional flow reserve overestimation: a word of caution13
Direct oral anticoagulants for ventricular thrombus resolution: pilot trials show reassuring efficacy and safety compared to warfarin13
Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry13
Low-dose fibrinolysis during primary percutaneous intervention for preventing no-reflow: stepping back to move forward?13
Left atrial appendage closure for thrombus trapping: the international, multicentre TRAPEUR registry13
PCR London Valves - in person or online - an invaluable opportunity for exchange dedicated to advancing the treatment of valvular heart disease13
0.15664196014404